SARS-CoV-2疫苗接种后时间、年龄、性别和合并症对SARS-CoV-2感染住院患者COVID-19结局的影响
前瞻性研究纳入2021年9月1日至2022年9月1日连续收治的745例接种疫苗和451例未接种疫苗的SARS-CoV-2感染住院患者,调整年龄、性别、合并症和入院时WHO COVID-19临床进展评分后,接种疫苗与较低的需氧风险相关(OR 0.46;95%CI 0.32-0.65),接种后14-120天、121-180天和>180天OR分别为0.38、0.50和0.57;抗刺突Ig滴度>5000 U/ml与需氧风险降低相关(OR 0.52;95%CI 0.30-0.92)。
要点
- 接种疫苗患者较未接种者需氧风险降低,调整后OR 0.46(95%CI 0.32-0.65)。
- 接种后14-120天、121-180天和>180天需氧OR分别为0.38、0.50和0.57。
- 抗刺突Ig滴度>5000 U/ml与需氧风险降低相关,OR 0.52(95%CI 0.30-0.92)。
核心结论
- 本研究表明COVID-19疫苗接种对住院患者的COVID-19结局有显著影响。
研究设计与样本
- 前瞻性研究,连续纳入2021年9月1日至2022年9月1日某COVID-19医院收治的745例接种疫苗和451例未接种疫苗的SARS-CoV-2感染住院患者。
主要发现
- 与未接种病例相比,接种疫苗患者年龄更大、合并症更多,但调整年龄、性别、合并症和入院时WHO COVID-19临床进展评分后需氧风险更低(OR 0.46;95%CI 0.32-0.65)。
- 接种后14-120天、121-180天和>180天患者需氧OR分别为0.38(95%CI 0.24-0.61)、0.50(95%CI 0.30-0.83)和0.57(95%CI 0.34-0.96)。
- 抗刺突Ig滴度>5000 U/ml与需氧风险降低相关(OR 0.52;95%CI 0.30-0.92)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the impact of COVID-19 vaccination on disease outcome in hospitalized patients with SARS-CoV-2 infection with a prospective study. 745 vaccinated and 451 unvaccinated patients consecutively admitted to a COVID-19 Hospital from 1st September 2021 to 1st September 2022 were included. Compared with unvaccinated cases, vaccinated patients were older, had more comorbidities, but had a lower risk of O2 need (odds ratio, OR, 0.46; 95 % CI 0.32-0.65) by logistic regression analysis adjusted for age, sex, comorbidity and WHO COVID-19 Clinical Progression Scale at admission. The ORs for O2 need were 0.38 (0.24-0.61), 0.50 (0.30-0.83) and 0.57 (0.34-0.96) in patients vaccinated 14-120, 121-180 and > 180 days prior to hospitalization, respectively. An anti-spike Ig titer higher than 5000 U/ml was associated with a reduced risk of O2 need (OR 0.52; 95 % CI 0.30-0.92). This study shows that COVID-19 vaccination has a significant impact on COVID-19 outcomes in hospitalized patients.
引用
- Donato F, Pilotto A, Focà E, et al. The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection. Vaccine. 2024. PMID: 38355322. doi:10.1016/j.vaccine.2024.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。